CD274 and ovarian carcinoma: Preclinical studies have shown that cisplatin increases PD-L1 expression and stability on ovarian cancer cells by activating the cGAS-STING signaling pathway [167], which enhances production of type I IFN and other immunomodulatory molecules, and increases recruitment of DCs and CD8+ T cells [168].